Abstract:The 3C-like proteinase (3CLpro) of severe acute respiratory syndrome (SARS) coronavirus has been proposed to be a key target for anti-SARS drug discovery. It has been proposed and verified that the dimer was the active form of 3CLpro and only one protomer is active In our previous work, we measured the dissociation constant (K-d) of the purified SARS 3CLpro using analytical ultracentrifugation at around 14.0 mu mol . L-1 Using this K-d value, most of the SARS 3CLpro in the in vitro activity assay (1-3 mu m . L-1) might be in the monomer form and inactive. To explain this dilemma, we measured the enzyme activity change together with the enzyme concentration. By fitting the concentration dependent activity profile, the apparent dissociation constant was found to be 094 mu mol . L-1. Indicating a clear tendency toward substrate enhanced dimerization. This also explains why SARS 3CLpro was still active in the in vitro activity assay under a relatively low enzyme concentration. To further verify the substrate induced dimerization phenomenon, we selected a previously reported SARS 3CLpro isatin inhibitor, 1-(2-naphthlmethyl) isatin-5-carboxamide (5f), which has similar binding interactions with the substrate and we studied its influence on SARS 3CLpro dimer formation using analytical ultracentrifugation 5f showed a strong ability to Induce SARS 3CLpro dimer formation By measuring the dimer and monomer distribution under different 5f concentrations, the EC50 of dirtier induction was found to be about 1.0 mu mol . L-1 under an enzyme concentration of 3 0 mu mol . L-1. This implies that only one protomer in the SARS 3CLpro choler binds to the inhibitor or the substrate. As the apparent association constant and thus the enzyme activity of SARS 3CLpro increases with the concentration of the substrate, this may be a smart way to allostetrically regulate the hydrolysis of the SARS viral polyproteins and the correct assembly of virons

Isatin Dual Functional Inhibitors: Modulating the Aggregation State and Enzyme Activity of SARS-3CL Proteinase

Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase.

The N-Terminal Octapeptide Acts As A Dimerization Inhibitor of Sars Coronavirus 3C-Like Proteinase

Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors.

Design and synthesis of isatin derivatives as effective SARS‐CoV‐2 3CL protease inhibitors

Substrate Binding and Homo-Dimerization of SARS 3CL Proteinase Are Mutual Allosteric Effectors

Exploring the Efficacy of Noncovalent SARS-CoV-2 Main Protease Inhibitors: A Computational Simulation Analysis Study.

Greener liquid-phase synthesis and the ACE inhibitory structure-activity relationship of an anti-SARS octapeptide.

Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease

Structure-based Design, Synthesis, and Biological Evaluation of Peptidomimetic SARS-CoV 3clpro Inhibitors

Design and evaluation of peptide inhibitors targeting the dimerization of SARS‐CoV‐2 main protease

Kinetic and Crystallographic Analyses of Sars Coronavirus 3clpro Inhibitors

Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety

Potent Inhibitors of SARS-CoV-2 3C-Like Protease Derived from N-substituted Isatin Compounds

Inhibition of the Main Protease 3CL-pro of the Coronavirus Disease 19 via Structure-Based Ligand Design and Molecular Modeling

The interaction between severe acute respiratory syndrome coronavirus 3C-like proteinase and a dimeric inhibitor by capillary electrophoresis.

Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-Like Proteinase

Virtual Screening of Novel Noncovalent Inhibitors for Sars-Cov 3C-Like Proteinase

Design and Synthesis of Potent HIV-1 Protease Inhibitors with (S)-Tetrahydrofuran-tertiary Amine-Acetamide As P2−ligand: Structure−activity Studies and Biological Evaluation

Design and Synthesis of Peptidomimetic Severe Acute Respiratory Syndrome Chymotrypsin-Like Protease Inhibitors.

Molecular modeling and chemical modification for finding peptide inhibitor against severe acute respiratory syndrome coronavirus main proteinase.